Skip to main content

Table 5 Comparison of [18F]FDG PET/MRI with ceMRI and/or ceCT for patient-based T, N and M staging, detection of residual disease after neoadjuvant chemotherapy and detection of recurrence

From: Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer

  [18F]FDG PET/MRI (95% CI) ceMRI and ceCT (95% CI) P
Primary tumor
 Sensitivity 97.4% (0.90–1.00) (37/38) 97.4% (0.89–1.00) (37/38)  
 Specificity 86.2% (0.77–0.89) (25/29) 58.6% (0.48–0.61) (17/29)  
 Accuracy 92.5% (0.84–0.95) (62/67) 80.6% (0.72–0.83) (54/67) 0.01
T staging
 Accuracy 96.4% (0.96–0.96) (54/56) 92.9% (0.93–0.93) (52/56) 0.48
T2a (growth into uterus, fallopian tubes, or ovaries)
 Sensitivity 100% (0.43–1.00) (2/2) 50% (0.11–0.50) (1/2)  
 Specificity 100% (0.96–1.00) (30/30) 100% (0.97–1.00) (30/30)  
 Accuracy 100% (0.93–1.00) (32/32) 96.9% (0.92–0.97) (31/32) 1.00
T2b (growth into other nearby pelvic organs such as bladder, sigmoid colon, or rectum)
 Sensitivity 0% (0.00–0.00) (0/1) 0% (0.00–0.00) (0/1)  
 Specificity 100% (1.00–1.00) (31/31) 100% (1.00–1.00) (31/31)  
 Accuracy 96.9% (0.97–0.97) (31/32) 96.9% (0.97–0.97) (31/32) 1.00
T3b (growth into organs outside the pelvis, but ≤ 2 cm across)
 Sensitivity 95.5% (0.86–0.96) (21/22) 90.9% (0.81–0.91) (20/22)  
 Specificity 100% (0.94–1.00) (33/33) 100% (0.93–1.00) (33/33)  
 Accuracy 98.2% (0.91–0.98) (54/55) 96.4% (0.88–0.96) (53/55) 1.00
T3c (growth into organs outside the pelvis, > 2 cm across)
 Sensitivity 100% (0.92–1.00) (21/21) 100% (0.92–1.00) (21/21)  
 Specificity 100% (0.95–1.00) (34/34) 100% (0.95–1.00) (34/34)  
 Accuracy 100% (0.94–1.00) (55/55) 100% (0.94–1.00) (55/55) 0.00
N staging
 Sensitivity 100% (0.74–1.00) (6/6) 33.3% (0.12–0.33) (2/6)  
 Specificity 100% (0.93–1.00) (21/21) 100% (0.94–1.00) (21/21)  
 Accuracy 100% (0.88–1.00) (27/27) 85.2% (0.76–0.85) (23/27) 0.13
M staging
 Sensitivity 100% (0.94–1.00) (12/12) 25.0% (0.19–0.25) (3/12)  
 Specificity 100% (0.25–1.00) (1/1) 100% (0.22–1.00) (1/1)  
 Accuracy 100% (0.88–1.00) (13/13) 30.8% (0.19–0.31) (4/13)  < 0.01
Evaluation of residual disease for interval debulking surgery after neoadjuvant chemotherapy
 Sensitivity 71.4% (0.71–0.71) (5/7) 57.1% (0.57–0.57) (4/7)  
 Specificity 0% (0.00–0.00) (0/0) 0% (0.00–0.00) (0/0)  
 Accuracy 71.4% (0.71–0.71) (5/7) 57.1% (0.57–0.57) (4/7) 1.00
Evaluation of recurrence
 Sensitivity 100% (0.88–1.00) (9/9) 88.9% (0.76–0.89) (8/9)  
 Specificity 100% (0.44–1.00) (2/2) 100% (0.40–1.00) (2/2)  
 Accuracy 100% (0.80–1.00) (11/11) 90.9% (0.69–0.91) (10/11) 1.00